UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE TO
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
THESEUS PHARMACEUTICALS, INC.
(Name of Subject Company (Issuer))
CONCENTRA MERGER SUB II, INC.
(Name of Filing Persons (Co-Offeror 1))
CONCENTRA BIOSCIENCES, LLC
(Name of Filing Persons (Parent of Offeror))
TANG CAPITAL PARTNERS, LP
(Name of Filing Persons (Co-Offeror 2))
TANG CAPITAL MANAGEMENT, LLC
(Name of Filing Persons (Co-Offeror 3))
Common Stock, Par Value $0.0001 Per Share
(Title of Class of Securities)
88369M101
(CUSIP Number of Class of Securities)
Kevin Tang
Concentra Biosciences, LLC
4747 Executive Drive, Suite 210
San Diego, California 92121
Tel. (858) 281-5372
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications on Behalf of Filing Persons)
Copies to:
Ryan A. Murr
Robert W. Phillips
Gibson, Dunn & Crutcher LLP
One Embarcadero Center Suite 2600
San Francisco, CA 94111
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
Check the appropriate boxes below to designate any transactions to which the statement relates:
☒ | | | third-party tender offer subject to Rule 14d-1. |
☐ | | | issuer tender offer subject to Rule 13e-4. |
☐ | | | going-private transaction subject to Rule 13e-3. |
☐ | | | amendment to Schedule 13D under Rule 13d-2. |
Check the following box if the filing is a final amendment reporting the results of the tender offer. ☐
If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:
☐ | | | Rule 13e-4(i) (Cross-Border Issuer Tender Offer) |
☐ | | | Rule 13d-1(d) (Cross-Border Third-Party Tender Offer) |